Wang & Lee Group board approves 250-to-1 reverse share split
On Monday, Stifel analysts reiterated their Buy rating and $135.00 price target for Abbott Laboratories (NYSE:ABT), a prominent $220 billion healthcare equipment leader, following recent developments in the company’s Electrophysiology (EP) market offerings. According to InvestingPro, Abbott maintains strong market presence with $42 billion in annual revenue and consistently low stock price volatility. Abbott has made a notable entry into the pulsed-field-ablation (PFA) market with the CE Mark/EU approval of its Volt balloon-in-basket PFA system in late March 2025.
The European Heart Rhythm Association (EHRA) 2025 medical meeting featured a six-month data read-out of the Volt system. The results were promising, with an adverse event rate reported at 2.7%, which aligns with rates from other PFA systems. The data also showed a high efficacy rate with approximately 88% of paroxysmal afib patients and about 77% for persistent afib patients experiencing freedom from arrhythmia re-occurrence.
These outcomes have caught the attention of the medical community, particularly among high-volume electrophysiologists. One such early adopter of the Volt system, who performed over 400 afib ablations in 2024, expressed enthusiasm about the system’s capabilities and potential impact on the European EP market, valued at over $2 billion. The company’s strong market position is reflected in its broader analyst consensus, with an average rating of 1.78 (where 1 is Strong Buy) and price targets ranging from $111 to $158.
Stifel’s continued confidence in Abbott is bolstered by the positive feedback and promising data surrounding the Volt system. With the EP market rapidly evolving, Abbott’s advancements position the company favorably within this specialized healthcare segment.
The reaffirmation of the Buy rating and price target by Stifel reflects the firm’s outlook on Abbott’s market position and the anticipated influence of the Volt system on the company’s growth within the EP market. Trading at a P/E ratio of 16.7 and maintaining a "GREAT" financial health score on InvestingPro, Abbott’s shares are being closely watched as the company progresses in this innovative field of cardiac care. For deeper insights into Abbott’s valuation and 10+ additional ProTips, explore the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Abbott Laboratories has reported significant developments across its business segments. The company demonstrated strong growth in its Medical (TASE:BLWV) Devices division, with fourth-quarter results showing robust revenue increases in Diagnostics, Nutrition, and Established Pharmaceuticals. Abbott also received a CE Mark for its Volt PFA catheter, allowing for its commercialization in the European Union, marking a regulatory milestone achieved ahead of schedule. Analysts from TD Cowen, Oppenheimer, Piper Sandler, and BTIG have all maintained positive ratings on Abbott, with price targets ranging from $133 to $140, reflecting confidence in the company’s growth prospects.
TD Cowen’s Joshua Jennings expressed optimism about Abbott’s ability to meet or exceed earnings estimates, highlighting new product rollouts as key growth drivers. Oppenheimer analysts noted Abbott’s strong relationships in the electrophysiology market as a significant competitive advantage, while Piper Sandler emphasized the potential for Abbott’s structural heart business to drive double-digit growth. BTIG analysts praised the company’s progress in its PFA program, noting the early CE Mark approval and the Volt-AF U.S. IDE trial’s ahead-of-schedule enrollment completion.
These recent developments underscore Abbott’s strategic execution and market positioning, as the company continues to expand its presence in key medical technology sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.